Skip to main content

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Active, not recruiting · Phase 3 · NCT03900429

Conditions: NASH - Nonalcoholic Steatohepatitis

At a glance

Research payments reported, 2025
$8.1M
U.S. investigators named
74
Sites paid
58
Planned or actual enrollment
1,759

About the trial

Sponsor
Madrigal Pharmaceuticals, Inc.
Tested
MGL-3196 (drug), Placebo (drug), Liver Biopsy (procedure)
Dates
Started 2019-03-28; completion 2028-01
Results posted
Not yet

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

From ClinicalTrials.gov, last updated 2026-06-01. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Madrigal Pharmaceuticals reported $8.1M in research payments for this study in 2025 (1,436 payments).

Products named: Rezdiffra

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Covenant Metabolic Specialists LLC $846,426
  • Pinnacle Clinical Research PLLC $630,713
  • Dhr Health Institute for R&d $610,432
  • South Texas Research Institute $580,375
  • Fresno Clinical Research Center $542,244
  • The Institute for Liver Health II LLC $497,665
  • Adobe Clinical Research LLC $423,644
  • Duke University $337,558
  • Florida Digestive Health Specialists LLP $238,133
  • Kansas Medical Clinic PA $208,243
  • Texas Digestive Disease Consultants PLLC $192,539
  • Premier Medical Group PC $170,289
  • Excel Medical Clinical Trials LLC $165,400
  • Lucas Research Inc $153,430
  • Gastrointestinal Associates PA $146,001
  • Velocity Clinical Research Inc $143,586
  • Kansas City Research Institute LLC $127,552
  • Methodist Dallas Medical Center, TX $121,103
  • Virginia Commonwealth University $118,159
  • South Denver Gastroenterology PC $114,777
  • Richmond Institute for Veterans Research $113,046
  • Gastrointestinal Specialists of Georgia PC $111,724
  • Cedars-Sinai Medical Center, CA $101,899
  • Aventiv Research Inc $101,057
  • Ochsner Medical Center Acute, LA $97,824
  • Gia Clinical Trials LLC $93,551
  • Fundacion De Investigacion De Diego Inc $76,809
  • Gcga Physicians LLC $76,439
  • Digestive Health Research LLC $73,824
  • Tandem Clinical Research LLC $72,260
  • University of California San Diego $69,755
  • The Geneva Foundation $68,506
  • St Louis University $53,724
  • Gastroenterology Center of the Midsouth PLLC $49,003
  • American Research Corporation $47,929
  • Coastal Research Institute LLC $45,415
  • Bd of Trus of the Leland Stanford Jr Univ $44,509
  • Northwestern University $39,075
  • Gastroenterology Center of the Midsouth PLLC $34,344
  • Nature Coast Clinical Research $34,138
  • Arkansas Gastroenterology PA $33,856
  • San Fernando Valley Health Institute LLC $32,875
  • Delta Research PArtners LLC $31,919
  • University of Virginia Medical Center, VA $31,750
  • Bon Secours Mercy Health Inc $25,879
  • University of Kansas Medical Center Research Institute Inc $22,628
  • The University of Chicago $21,802
  • Unc School of Medicine $18,963
  • University of Utah $15,975
  • Liver Associates of Texas PA $13,525
  • The Administrators of Tulane Edu Fund $13,503
  • Weill Medical College of Cornell Univ $13,461
  • Compass Research LLC $13,000
  • Mount Sinai School of Medicine $11,546
  • Beth Israel Deaconess Medical Center, MA $5,250
  • Southern Therapy and Advanced Research LLC $2,048
  • Aes the Villages $1,573
  • Aes Dallas $1,144

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.